Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• "Non merci"
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Refer a friend or colleague
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection FEATURED REVIEW First-line therapy for patients with HIV infection is usually based on triple therapy. When sustained virological suppression has been achieved, treatment "simplification" can sometimes be considered. Is the two-drug regimen dolutegravir + rilpivirine (Juluca°) any better than other treatment options? Full review (3 pages) available for download by subscribers. 1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the November issue of Prescrire International - Gliptins: joint pain and exposure to NSAIDs FREE DOWNLOAD In the Adverse Effects section of the November issue, the results of a study by the independent French medical journal Prescrire, based on data from France's national health insurance system. Full text available for free download. 1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New special section: "Mediator° - the criminal trial" The independent French medical journal Prescrire began asking questions about the appetite-suppressant drug Mediator° (benfluorex) in 1986, and called for its withdrawal some 12 years before the French authorities finally took action. Meanwhile thousands of patients suffered serious, sometimes fatal, adverse effects. As the criminal trial opens in France, Prescrire looks back over the disaster, and analyses just what is at stake. 09 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Gemtuzumab ozogamicin (Mylotarg°) in acute myeloid leukaemia: no proven benefits According to currently available clinical evaluation data, gemtuzumab ozogamicin (Mylotarg°) does not provide tangible benefits for patients with acute myeloid leukaemia. 1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Fenspiride (Pneumorel°): serious adverse effects reported over two decades Despite serious adverse effects reported for more than 20 years, fenspiride (Pneumorel°) was only withdrawn from the market in 2019. 1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Industrial protectionism and medicines: too many damaging effects Pharmaceutical companies benefit from strong industrial protection which allows them to charge exorbitant prices for their medicines for a very long time. 1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ The European Medicines Agency's independence is paramount: concrete alternatives to the fee-for-service system must be found  ADVANCING HEALTHCARE POLICY  Prescrire's response to a public consultation on the revision of the EMA fee system, Prescrire emphasises that EMA needs to be weaned off a fee-for-service relationship with pharmaceutical companies and funded through public funding from the European Union. 1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Faces of Mediator", a new book published by Prescrire It was after seeing the French film "La Fille de Brest", an adaptation of the book by pulmonologist and whistle-blower Irène Frachon, that the photographer Marc Dantan first got the idea of taking portraits of the victims of Mediator° (benfluorex), in the hope that "bringing faces into the light could perhaps raise awareness of the silent suffering". That was the beginning of this book, which presents in 208 pages some 180 photographs, along with a foreword by Irène Frachon, a summary of the history of the Mediator° disaster, and an afterword by Prescrire. Texts in French and English. 1 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Emicizumab in haemophilia A • Colchicine and acute pericarditis • Lamotrigine: preventing severe cutaneous adverse reactions • NSAIDs: nephrotoxicity in young, healthy adults • New drugs: the key role of publicly-funded research in the United States... > Subscribe now 1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International Subscribe now Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 December 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2019", new from the editors of Prescrire International  NEW: FREE SPECIAL EDITION  Check out this brand new sampling of texts selected by our editors to introduce you to Prescrire International, a wholly independent monthly journal, written by and for healthcare professionals 28 August 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 September 2018

• Sitemap |
• Terms of use |
• Contact
• |Top of page